Comparative Pharmacology
Head-to-head clinical analysis: POLYCILLIN PRB versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYCILLIN PRB versus VEETIDS 500.
POLYCILLIN-PRB vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic